S100A9+CD14+ monocytes contribute to anti-PD-1 immunotherapy resistance in advanced hepatocellular carcinoma by attenuating T cell-mediated antitumor function

Xiaoxuan Tu,Longxian Chen,Yi Zheng,Chenglin Mu,Zhiwei Zhang,Feiyu Wang,Yiqing Ren,Yingxin Duan,Hangyu Zhang,Zhou Tong,Lulu Liu,Xunqi Sun,Peng Zhao,Lie Wang,Xinhua Feng,Weijia Fang,Xia Liu

DOI: https://doi.org/10.1186/s13046-024-02985-1

IF: 12.658

2024-03-10

Journal of Experimental & Clinical Cancer Research

Abstract:The paucity of reliable biomarkers for predicting immunotherapy efficacy in patients with advanced hepatocellular carcinoma (HCC) has emerged as a burgeoning concern with the expanding use of immunotherapy. This study endeavors to delve into the potential peripheral biomarkers capable of prognosticating efficacy in HCC patients who are poised to receive anti-PD-1 monotherapy within the phase III clinical trial, KEYNOTE394. Additionally, we sought to elucidate the underlying molecular mechanisms for resistance to immune checkpoint blockade (ICB) and propose innovative combination immunotherapy strategies for future clinical application.

oncology